Prior to in vivo studies, by using the xCELLigence platform for a read-out over 30hours, it has been shown that epigenetic upregulation of NY-ESO-1 by DAC sensitize 2 glioblastoma cell lines to NY-ESO-1–T cells killing, at the physiological ratio of 1:1.